Soleus Capital Management’s CG Oncology CGON Stock Holding History

Soleus Capital Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355K	Sell	5,000 -15,000	-75%	-$981K	0.01%	93
2026 Q1	$1.35M	Sell	20,000 -150,000	-88%	-$8.5M	0.05%	81
2025 Q4	$7.06M	Sell	170,000 -120,000	-41%	-$4.97M	0.26%	60
2025 Q3	$11.7M	Buy	290,000 +135,000	+87%	+$3.92M	0.59%	40
2025 Q2	$4.03M	Sell	155,000 -148,585	-49%	-$3.58M	0.27%	58
2025 Q1	$7.43M	Sell	303,585 -25,000	-8%	-$703K	0.54%	44
2024 Q4	$9.42M	Sell	328,585 -12,000	-4%	-$411K	0.59%	40
2024 Q3	$12.9M	Sell	340,585 -84,000	-20%	-$2.94M	1%	35
2024 Q2	$13.4M	Buy	424,585 +206,714	+95%	+$7.16M	1.18%	32
2024 Q1	$9.56M	Buy	+217,871	New	+$8.9M	0.71%	42

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Soleus Capital Management's CGON Position: Q2 2026 in Review

Soleus Capital Management reduced its CG Oncology (CGON) stake by 75% in Q2 2026, selling an estimated $981K and leaving 5,000 shares worth $355K. The position accounts for 0.01% of the portfolio, ranked #93.

Soleus Capital Management first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $13.4M in Q2 2024. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Soleus Capital Management held 5,000 shares of CG Oncology worth $355K as of Q2 2026.
Soleus Capital Management sold 15,000 CG Oncology shares in Q2 2026, an estimated $981K.
CG Oncology made up 0.01% of Soleus Capital Management's portfolio in Q2 2026, its #93 holding.
Soleus Capital Management first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
Soleus Capital Management's CG Oncology position peaked at $13.4M in Q2 2024.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.